In extended stage small cell lung cancer patients, adding PD-1/PD-L1 inhibitors to chemotherapy has already been reported to lead to a higher incidence of hyponatremia, and hypothyroidism [38]. This evidence concerns the gene CD274 and Hyponatremia.